Effectiveness of Glucocorticoids in the No-Reflow Phenomenon in STEMI Patients
Abstract
Relevance. The driving force behind the pathogenesis of no-reflow, as a component of ischemic-reperfusion injury, is myocardial edema, which provokes extravascular compression of the infarct-related artery (IRA), making it impossible to restore antegrade blood flow. Targeting edema is a promising approach in the treatment of this condition.
Aim. To analyze different strategies for managing no-reflow and to present data on the intracoronary single-dose administration of glucocorticoids in terms of their ability to improve blood flow gradation according to the TIMI scale during primary PCI in STEMI patients.
Materials and methods. During the period 2022–2024, 26 STEMI patients with no-reflow (TIMI 0/1 after stent implantation) were selected and divided into two groups of 13 patients each. The main group received a single intracoronary selective injection of methylprednisolone (250 mg) via a microcatheter into the IRA. The control group did not receive intracoronary pharmacotherapy for no-reflow, only hemodynamic support in case of hemodynamic deterioration.
Results. The most significant risk factor for the occurrence of no-reflow was found to be a prolonged period of acute myocardial ischemia, which, in our study, lasted 18 hours from the onset of symptoms. Regarding the effect of glucocorticoids, it was observed that when using methylprednisolone, administered according to the approved methodology, an increase in blood flow from TIMI 0 to TIMI 3 was achieved in 61.5% of cases. Compared with the control group, the angiographic effectiveness of this new treatment for the no-reflow phenomenon reached 53.8%. In-hospital mortality did not differ significantly between the two groups (38.46% vs. 53.85%).
Conclusions. The duration of acute myocardial infarction symptoms is a crucial risk factor for the no-reflow phenomenon during primary PCI. This study demonstrates that the use of glucocorticoids can help restore blood flow in no-reflow cases. Achieving TIMI 3 blood flow following a single intracoronary injection of methylprednisolone occurred in 61.5% of patients in the treatment group. Compared with the control group, the effectiveness of this new method reached 53.8%. Despite the improvement in TIMI flow, it was not possible to reduce in-hospital mortality in patients receiving hormone therapy.
References
2. Simsek B, Rempakos A. International Psychological Well-Being Survey of Interventional Cardiologists. JACC Cardiovasc Interv. 2023 Jun 12;16(11):1401-1407. http://dx.doi.org/10.1016/j.jcin.2023.03.033
3. Papapostolou S, MBBS, FRACP; Nick Andrianopoulos, MBBS, MBiostat. Long-term clinical outcomes of transient and persistent no- reflow following percutaneous coronary intervention (PCI): a multicentre Australian registry. EuroIntervention. 2018;14:185-193. https://doi.org/10.4244/eij-d-17-00269
4. Gjin Ndrepepa. No-reflow after percutaneous coronary intervention: a correlate of poor outcome in both persistent and transient forms. EuroIntervention. 2018;14:139-141. https://doi.org/10.4244/eijv14i2a21
5. Salo SV, Shumakov VO, Shpak SS, Tokhtarov VV. Myocardial ischemia – reperfusion injury. Zaporozhye Medical Journal. 2023Sep.;25(5):455-60. DOI: https://doi.org/10.14739/2310-1210.2023.5.279461
6. Whitcup SM, Cidlowski JA. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59:1–12. DOI: 10.1167/iovs.17-22259
7. Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev. Rheumatol. 2020;16:44–133. http://dx.doi.org/10.1038/s41584-020-0371-y
8. Schimmer BP, Funder JW. Hormona adrenocorticotrópica, esteroides suprarrenales y corteza suprarrenal. In: Las bases farmacológica de la terapéutic. 13.ª ed. Goodman Gilman; 2019. p. 845-61. https://accessmedicina.mhmedical.com/content.aspx?bookid=2457§ionid=200158048
9. Scherholz ML, Schlesinger N. Chrono pharmacology of glucocorticoids. Adv Drug Deliv Rev. 2019;151–152:245– 61, http://dx.doi.org/10.1016/j.addr.2019.02.004
10. Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9:2709. http://dx.doi.org/10.3390/jcm9092709
11. Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (United Kingdom). 2022;61:1760–8, http://dx.doi.org/10.1093/rheumatology/keac115 Таблиця 5 Значення імовірності досягнення градацій ТІМІ в порівнянні основної та контрольної групи Кровотік ТІМІ P-value ТІМІ 0 0.0036 ТІМІ 1 1.0 ТІМІ 2 0.645 ТІМІ 3 0.0112
